Parkinson's disease (PD) is a common progressive, neurodegenerative brain disease that is promoted by mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction in the brain. Compared with computer tomography (CT) or magnetic resonance imaging (MRI), non-invasive nuclear radiopharmaceuticals have great significance for the early diagnosis of PD due to their high sensitivity and specificity in atypical and preclinical cases. Based on the development of coordination chemistry and chelator design, radionuclides may be delivered to lesions by attaching to PD-related transporters and receptors, such as dopamine, serotonin, and others. In this review, we comprehensively detailed the current achievements in radionuclide imaging in Parkinson's disease.
INTRODUCTION
As the second most widespread neurodegenerative disease in elderly people, Parkinson's disease (PD) is characterized by cardinal motor symptoms, including tremor, rigidity, bradykinesia and postural instability [1] . The histopathological hallmarks of PD are dopamine depletion in the striatum, which results from the progressive degeneration of the substantial nigral dopamine neurons in patient brains [2, 3] . Certain etiopathogenic processes, such as mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction, are thought to promoted PD, which can lead to nigrostriatal cell dysfunction and death [4] .
The prevalence rate of PD increases with age, and the overall prevalence of PD has recently been increasing because of an aging population [5] . Currently, the diagnosis of PD is primarily based on clinical symptoms, in addition to a favorable response to levodopa therapy [6, 7] . Therefore, rigorous diagnostic criteria are necessary to ensure that the diagnosis is applied consistently and reliably.
Almost 25% of PD patients with an antemortem clinical diagnosis were found to have no PD during postmortem examinations in clinical-pathological studies [8] . PD patients manifest symptoms only when 50 to 80% of the nigrostriatal neurons are lost. Clinical methods are not able to provide an early diagnosis before a significant loss of dopamine neurons has occurred. Computer tomography or magnetic resonance imaging can be used to diagnose Parkinson's disease, but they have obvious disadvantages, such as low sensitivity and specificity, particularly in certain atypical or preclinical cases. However, PD patients would benefit from early *Address correspondence to this author at the Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan (610041), PR China; Tel: +86-28-85423089; Fax: +86 28 85582944; E-mail: zhiyunjia@hotmail.com # These authors contributed equally to this work. diagnosis, particularly before severe dopamine neuron loss. Therefore, improvements to the accuracy of PD clinical diagnoses are necessary, and non-invasive nuclear imaging agents and nuclear imaging technology may provide these improvements.
Nuclides-based positron imaging tomography (PET) or single photon emission computed tomography (SPECT) imaging methods are emerging techniques for the diagnosis, staging and evaluation of PD as many new types of nuclear imaging agents are being developed and clinically applied [8] . After decades of research in the field, some progress has been made and imaging agents that are targeted to PD have become a popular research topic in the field of nuclidesbased imaging.
The study of PD imaging agents has developed for decades and has greatly progressed [9] [10] [11] [12] [45, 46] and [ 123 I]-meta-iodobenzylguanidine (MIBG) (Fig. 2) [47] [48] [49] [50] [51] have also been used to evaluate cardiac sympathetic loss in PD [52] .
Dopamine Transporter
The dopamine transporter (DAT) is a transmembrane protein that transports dopamine out of the neuron synapse and into the presynaptic cytoplasm. DAT is specifically expressed in DA neurons and its density highly corresponds to the number of DA neurons; therefore, DAT may be used to reflect the functional changes in DA neurons [53] . Physiological studies have indicated that DAT facilitates consistence of cellular DA, regulates DA signal intensity, and controls DA cleaning in synaptic gaps [54] . It has been demonstrated that in idiopathic Parkinson's disease patients, DAT dramatically declined in the brain along with dopaminergic system degeneration; therefore, DAT nuclear imaging is thought to be a potential biomarker for the diagnosis of DA degeneration [55] [56] [57] [58] [59] .
The presynaptic terminals in the central nervous system (CNS) can be imaged using DAT probes, such as cocaine analogs, [66] [67] [68] [71, 72] and others (Fig. 3) . Consequently, dopamine release can be evaluated indirectly to diagnose Parkinson's disease because DAT levels at the presynaptic site are able to be quantified. 123 I]FP-CIT has also been used for the early diagnosis, PD follow-up and monitoring DAT changes in Parkinson's disease patients [74] [75] [76] [77] . A [
11 C]FE-CIT PET assessment demonstrated that the severity of nigrostriatal damage was not dependent on the age at onset during the early disease phase of sporadic PD patients [78] . Furthermore, [ 18 F]FECNT evaluation indicated that PD heritability may be associated with more severe and widespread genetic dopaminergic injury [79] . The β-CIT striatal-to-nonspecific binding ratios in patient brains were evaluated using [ 123 I]β-CIT and a significantly increased S/N ratio was observed after selective serotonin reuptake inhibitor (SSRI) treatment [80] [81] [82] [83] . A more recent study determined that SSRI paroxetine treatment was able to significantly increase the quantification of striatal [ 123 Masilamoni et al [78] (Fig. 4) 
Vesicular Monoamine Transporter Imaging Agent
The vesicular monoamine transporter (VMAT) is a transport protein complex that is responsible for transporting monoamine neurotransmitters into the synaptic vesicles, which are releasing neurotransmitters into monoaminergic neurons. VMAT is known to transport several neurotransmitters, such as dopamine, serotonin, norepinephrine, epinephrine, histamine and others. One subtype of VMAT, VMAT 2 , is primarily expressed in a variety of monoaminergic cells in the CNS, such as mast cells, the sympathetic nervous system brain, and cells that contain histamine in the gut [114] . Because of these properties VMAT 2 was considered to be a novel PD imaging probe. VMAT 2 targeting produced excellent image quality and had the ability to differentiate reduced VMAT 2 uptake sites in patients with PD; these properties have made non-invasive nuclear VMAT 2 imaging a leader in the frontier of current PD imaging research. [117] .
5-HYDROXYTRYPTAMINE RECEPTOR AND TRANSPORTER IMAGING AGENTS
5-hydroxytryptamine (5-HT or serotonin) is an important monoamine neurotransmitter that is widely distributed in the brain. 5-HT is synthesized in the serotonergic neurons of the CNS and contributes to feelings of happiness. As neuropathology, neurochemistry and other related subjects have developed, there is the belief that 5-HT metabolic changes are important in the mechanism of PD. Recent research has determined that there is a significant decrease of the 5-HT transporter (SERT) in the striatum and other brain areas in PD patients [118] [119] [120] [121] [122] . Currently, there are several types of 5-HT relevant radiotracers available for imaging studies, including 5-HT 1A receptor imaging agents and 5-HT transporter (SERT) imaging agents [123] , etc.
The 5-HT 1A receptor is the most widespread subtype of 5-HT receptor, which is a G protein-coupled receptor and mediates inhibitory neurotransmission. 5-HT 1A receptor activation has been proven to increase dopamine release and may be useful for improving PD symptoms. [ 11 C]WAY-100635 (Fig. 6) (Fig. 8) . Among these agents, [ 18 F]McN5652 has been demonstrated to be suitable for SERT quantification using PET analysis in humans in in vivo studies [150] . The 18 F-labeled SERT radioligand, 4-[ 18 F]ADAM, has also been reported as a viable agent for both preclinical [143] and human studies [151] [152] [153] [154] .
Politis et al [126] observed significant [ 11 C]DASB binding reductions in the striatal, brainstem, and cortical regions in PD patients using [ 11 C]DASB PET in 30 PD patients. Progressive non-linear serotonergic dysfunction was investigated in PD patients, which appeared not to influence SERT binding and did not determine disability levels or chronic exposure to dopaminergic therapy. Li and co-workers [155] 123 I]ADAM suggests that it is possible to simultaneously evaluate dopaminergic and serotonergic system changes in PD models.
OTHER IMAGING AGENTS
There are a variety of agents that may be used in noninvasive nuclear PD imaging that are currently being tested in animal experiments or preclinical trials, such as [ 11 (Fig. 9) .
Recent results have demonstrated that in PD patients without dementia [161] , as well as de novo or early PD patients, AchE is particularly reduced in the posterior cingulate and posterior temporo-parieto-occipital associative cortex [162] . It has been proven that PD patients without dementia have more severe cholinergic deficits in these areas compared with patients with AD [156, 160] . Brain cholinergic dysfunction was observed at a very early stage of PD using [ 11 C]MP4A PET studies; furthermore, this dysfunction may precede the manifestation of motor symptoms. Interestingly, lower AChE activity in the cerebral cortex was also observed in the early PD group compared with the advanced PD group without dementia [156, 159] . A [
18 F]2FA PET study in PD patients observed decreasednicotinic receptors (nAChRs) in the nigrostriatal system, indicating that [
18 F]2FA could be a useful tool to study post-synaptic cholinergic transmission [158] .
In vivo SPECT imaging of muscarinic acetylcholine receptors using [ 123 I]QNB in patients with dementia with Lewy bodies and Parkinson's disease dementia determined that significantly elevated mAChRs in the occipital lobe were associated with DLB and PD [157] . A [ 11 C](R)-PK11195 PET study in patients with idiopathic Parkinson's disease confirmed that widespread microglial activation is associated with the PD pathological process [160] .
Parkinson's disease itself is not associated with a consistent pattern of cerebral blood flow alterations in the basal ganglia, but reduced parietal blood flow is often reported [163] . A recent study determined that hypoperfusion in the inferior frontal region can be observed in patients with Parkinson's disease with dementia using [ 99m Tc]HMPAO SPECT [164] (Fig. 9) . Brain perfusion imaging agents, such as [ 99m Tc]HMPAO, can also be used to measure cerebral tissue perfusion in PD patients [163] [164] [165] .
Several novel imaging approaches have been proposed that examine mitochondrial oxidative stress. Ikawa et al [166] evaluated a PET method using [ 62 Cu]-diacetyl-bis (N(4)-methyl-thiosemicarbazone) ([ 62 Cu]ATSM) (Fig. 9) to evaluate oxidative stress and the accompanying mitochondrial dysfunction during PD pathogenesis. Their study observed enhanced striatal oxidative stress, particularly in the contralateral striatum of PD patients compared with control subjects. Additionally, this increased oxidative stress was associated with the progression of disease severity. These findings indicate a potential correlation between oxidative stress and striatal neurodegeneration in PD.
CONCLUSIONS
During the past three decades, nuclear brain imaging has proven to be a promising, powerful and unique method for the evaluation of brain function during normal and disease states. Research investigating Parkinson's disease diagnosis has occurred in tandem with the rapid evolution of molecular imaging technologies and their applications in preclinical studies and clinical practice. Compared with traditional anatomical imaging technologies, PET nuclear imaging assessments provide spatial localization of metabolic changes as well as accurate and consistent quantification of their distribution. These properties have allowed PET nuclear imaging to be employed as a valuable tool during clinical neuro-disease examinations. These personalized highly sensitive and specific evaluations will be useful for the early diagnosis, prognosis and long-term follow up of Parkinson's disease.
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